Microdosing for Depression Appears to Work as Placebo
5 days ago
- #psychedelics
- #microdosing
- #placebo-effect
- Microdosing psychedelics like LSD or psilocybin was initially hailed for benefits such as increased focus, mood enhancement, and reduced depression.
- A recent Phase 2B trial by MindBio Therapeutics found that microdosing LSD was outperformed by a placebo in treating major depressive disorder.
- Patients given LSD microdoses showed improved well-being but worse depression scores compared to those given a caffeine placebo.
- The study suggests that placebo effects may be stronger than the actual pharmacological effects of microdosing.
- Previous research, including a 2020 study, demonstrated that participants reported psychedelic effects even when given a placebo, highlighting the power of expectation.
- MindBio's CEO Justin Hanka concluded that microdosing is ineffective for clinical depression, calling it a 'nail in the coffin' for such treatments.
- Critics like Jim Fadiman argue that the study's design, using caffeine as an active placebo, may have skewed results.
- Despite skepticism, some microdosing advocates, like author Ayelet Waldman, argue that perceived benefits—placebo or not—are valuable.
- MindBio is shifting focus away from microdosing research, with Hanka expressing regret over investing in the field.